Search Within

Matthew J Matasar

  1. "Center for Hematologic Malignancies"
  2. "Meeting abstract"
  3. "Solid Tumor Oncology Division"
Formats
  1. Meeting Abstract (26)
Groups
  1. Center for Hematologic Malignancies (26)
  2. Department of Medicine (26)
  3. Hematologic Malignancies, Division of (26)
  4. Lymphoma (26)
  5. Solid Tumor Oncology Division (26)
  6. Survivorship Research (26)

More Groups

People
  1. Andrew Zelenetz (25)
  2. David Straus (24)
  3. Pamela Drullinsky (24)
  4. Paul Hamlin (22)
  5. Anita Kumar (21)
  6. Audrey Hamilton (19)

More People

Years
  1. 2022 (1)
  2. 2021 (3)
  3. 2020 (2)
  4. 2019 (2)
  5. 2018 (2)
  6. 2017 (10)

More Years

Publications
  1. Blood (13)
  2. Hematological Oncology (6)
  3. Journal of Clinical Oncology (6)
  4. Clinical Lymphoma, Myeloma and Leukemia (1)
Publishers
  1. American Society of Hematology (13)
  2. American Society of Clinical Oncology (6)
  3. Wiley Blackwell (6)
  4. Elsevier Inc. (1)

Results (26)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2
    Meeting Abstract

    Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma
    Meeting Abstract

    Khan, N.; Khimani, F.; Shustov, A. R.; Shadman, M.; Ruan, J.; Moskowitz, A. J.; Straus, D. J.; Kumar, A.; Sauter, C. S.; Zelenetz, A. D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Provision of subspecialized expert oncology (SEO) opinions using Navya Cancer Data Model (NCDM), a technology-based platform: Prospective study to facilitate access to care
    Meeting Abstract

    Traina, T. A.; Kantoff, P. W.; Matasar, M. J.; Dunn, L.; Friedman, C. F.; Voss, M. H.; Seidman, A. D.; Cahlon, O.; Zauderer, M. G.; Manship, C.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Batlevi, C.; Drullinsky, P.; Grieve, C.; Laraque, L.; Joseph, A.; Mahajan, N.; Matasar, M.; Straus, D.; Zelenetz, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Interim analysis from a prospective multicenter study of next-generation sequencing minimal residual disease assessment and CT monitoring for surveillance after frontline treatment in diffuse large B-cell lymphoma
    Meeting Abstract

    Kumar, A.; Westin, J.; Schuster, S. J.; Nowakowski, G. S.; Lossos, I. S.; Batlevi, C. L.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Frontline sequential immunochemotherapy plus lenalidomide for mantle cell lymphoma incorporating MRD evaluation: Phase II, investigator-initiated, single-center study
    Meeting Abstract

    Epstein-Peterson, Z. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Ho, C.; Jacob, A. P.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin combined with AVD chemotherapy and radiotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L. E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S.; Drill, E.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase II, multicenter study of high dose chemotherapy with autologous stem cell transplant followed by maintenance therapy with romidepsin for T-cell lymphoma
    Meeting Abstract

    Khan, N.; Shustov, A. R.; Khimani, F.; Shadman, M.; Cassaday, R. D.; Ruan, J.; Moskowitz, A. J.; Zelenetz, A. D.; Noy, A.; Straus, D. J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Initial results of a phase II study of sequential chemotherapy and lenalidomide followed by rituximab and lenalidomide maintenance for untreated mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Zelenetz, A. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Laraque, L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma
    Meeting Abstract

    Batlevi, C. L.; De Frank, S.; Stewart, C.; Hamlin, P. A.; Matasar, M. J.; Gerecitano, J. F.; Moskowitz, A. J.; Hamilton, A. M.; Zelenetz, A. D.; Drullinsky, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save